Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7755)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
May 24, 2022 (publication date) through Nov 21, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Poulose JV, Kainickal CT. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials. World J Clin Oncol 2022; 13(5): 388-411 [PMID: 35662989 DOI: 10.5306/wjco.v13.i5.388] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v13/i5/388.htm |
| Number | Citing Articles |
| 1 |
Dong Hyun Kim, Mingu Kang, Gahee Park, Mohammad Mostafavi, Yoojoo Lim, Chan-Young Ock, Jiwon Koh, Yoon Kyung Jeon, Kyeong Cheon Jung, Soon-Hyun Ahn, Eun-Jae Chung, Seong-Keun Kwon, Bhumsuk Keam. Changes in the tumor microenvironment in recurrent head and neck squamous cell carcinoma and its implication on efficacy of immune checkpoint inhibitors. Discover Oncology 2024; 15(1) doi: 10.1007/s12672-024-01504-0
|
| 2 |
Miguel Caballero-Borrego, Aida Piedra, Óscar Gallego, Antonio López-Pousa, Paola Castillo, Pilar Navarrete, Alba Prat, Juan J. Grau. Walking one hour per day and the derived neutrophil-to-lymphocyte ratio are associated with outcome in palliative second-line immunotherapy for patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Brazilian Journal of Otorhinolaryngology 2024; 90(6): 101493 doi: 10.1016/j.bjorl.2024.101493
|
| 3 |
Svein Erik Moe, Fredrik A. Erland, Siren Fromreide, Stein Lybak, Marianne Brydoy, Harsh N. Dongre, Sophia M. Dhayalan, Daniela-Elena Costea, Olav K. Vintermyr, Hans Jørgen Aarstad. The TP53 Codon 72 Arginine Polymorphism Is Found with Increased TP53 Somatic Mutations in HPV(−) and in an Increased Percentage among HPV(+) Norwegian HNSCC Patients. Biomedicines 2023; 11(7): 1838 doi: 10.3390/biomedicines11071838
|
| 4 |
Armin Nejat Dehkordi, Moein Maddahi, Parinaz Vafa, Nasim Ebrahimi, Amir Reza Aref. Salivary biomarkers: a promising approach for predicting immunotherapy response in head and neck cancers. Clinical and Translational Oncology 2024; doi: 10.1007/s12094-024-03742-8
|
| 5 |
Ruby Dwivedi, Ayushi Jain, Shalini Gupta, Shaleen Chandra. Immunotherapy: The Fourth Domain in Oral Cancer Therapeutics. Indian Journal of Otolaryngology and Head & Neck Surgery 2024; 76(3): 2257 doi: 10.1007/s12070-024-04565-3
|
| 6 |
Martina Raudenská, Maria Bugajová, David Kalfeřt, Jan Plzák, Adam Šubrt, Petra Tesařová, Michal Masařík. The interplay between microbiome and host factors in pathogenesis and therapy of head and neck cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2024; : 189216 doi: 10.1016/j.bbcan.2024.189216
|
| 7 |
Yizhou Yang, Zeman Cai, Kaichun Huang, Mei Li, Xiao Wang, Yinbing Lin, Sijie Chen, Zhining Yang, Zhixiong Lin. A composite score based on immune-related gene prognostic index and m6A risk score of head and neck squamous cell carcinoma. Frontiers in Genetics 2023; 14 doi: 10.3389/fgene.2023.1061569
|
| 8 |
Alexis M. Sanwick, Ivis F. Chaple. Targeted radionuclide therapy for head and neck squamous cell carcinoma: a review. Frontiers in Oncology 2024; 14 doi: 10.3389/fonc.2024.1445191
|
| 9 |
Sonja Steen, Karl Semmelmayer, Christa Flechtenmacher, Jürgen Hoffmann, Kolja Freier, Dominik Horn, Jochen Hess, Christian Freudlsperger, Julius Moratin. Dynamic Up-Regulation of PD-L1 in the Progression of Oral Squamous Cell Carcinoma. International Journal of Molecular Sciences 2023; 24(22): 16386 doi: 10.3390/ijms242216386
|
| 10 |
Nidhi Anand, Pallavi Srivastava, Nuzhat Husain, Deeksha Agarwal, Anurag Gupta, Roma Pradhan. Evaluation of CTLA-4 and PD-L1 Expression in Thyroid Carcinoma and Its Prognostic Significance. Cureus 2024; doi: 10.7759/cureus.67004
|
| 11 |
Kedar Kirtane, Maie St. John, Harry Fuentes-Bayne, Sandip P. Patel, Armen Mardiros, Han Xu, Eric W. Ng, William Y. Go, Deborah J. Wong, John B. Sunwoo, John S. Welch. Genomic Immune Evasion: Diagnostic and Therapeutic Opportunities in Head and Neck Squamous Cell Carcinomas. Journal of Clinical Medicine 2022; 11(24): 7259 doi: 10.3390/jcm11247259
|
| 12 |
Ruey-Long Hong, Chia-Jui Yen, Ming-Yu Lien, Rebecca Cheng, Yu-Wen Su, Han-Nan Lin, Song Ling Poon, Chih-Yen Chien. Betel-nut chewing does not influence PD-L1 expression rates in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC): A prospective biomarker prevalence study. Oral Oncology 2024; 152: 106760 doi: 10.1016/j.oraloncology.2024.106760
|
| 13 |
Helene Hersvik Aarstad, Svein Erik Emblem Moe, Stein Lybak, Øystein Bruserud, Tor Henrik Anderson Tvedt, Hans Jørgen Aarstad. Plasma IL-1 and IL-6 Family Cytokines with Soluble Receptor Levels at Diagnosis in Head and Neck Squamous Cell Carcinoma: High Levels Predict Decreased Five-Year Disease-Specific and Overall Survival. Cancers 2024; 16(8): 1484 doi: 10.3390/cancers16081484
|
| 14 |
Jiaqi Han, Ni Zeng, Kun Tian, Zijian Liu, Longjiang She, Zhu Wang, Jinlan He, Nianyong Chen. First‐line immunotherapy combinations for recurrent or metastatic nasopharyngeal carcinoma: An updated network meta‐analysis and cost‐effectiveness analysis. Head & Neck 2023; 45(9): 2246 doi: 10.1002/hed.27452
|
| 15 |
Daniel A. Ruiz-Torres, Saskia Naegele, Archana Podury, Lori Wirth, Sophia Z. Shalhout, Daniel L. Faden. Immunotherapy time of infusion impacts survival in head and neck cancer: A propensity score matched analysis. Oral Oncology 2024; 151: 106761 doi: 10.1016/j.oraloncology.2024.106761
|
| 16 |
Dong Hyun Kim, Jong Seok Ahn, Mingu Kang, Gahee Park, Yoojoo Lim, Soohyun Hwang, Chan-Young Ock, Jiwon Koh, Eun-Jae Chung, Seong-Keun Kwon, Yoon Kyung Jeon, Kyeong Cheon Jung, Soon-Hyun Ahn, Bhumsuk Keam. Comparison of Tumor Microenvironments between Primary Tumors and Lymph Node Metastases in Head and Neck Squamous Cell Carcinoma and Their Predictive Role in Immune Checkpoint Inhibitor Treatment. Cells 2024; 13(18): 1557 doi: 10.3390/cells13181557
|
| 17 |
Maximilian Rink, Ernst-Michael Jung, Julian Künzel. The Use of Contrast-Enhanced Sonography for Therapy Monitoring of Metastatic Lymph Nodes: A Systematic Review. Current Oncology 2023; 30(7): 6734 doi: 10.3390/curroncol30070494
|
| 18 |
Katarzyna Starska-Kowarska. The Role of Different Immunocompetent Cell Populations in the Pathogenesis of Head and Neck Cancer—Regulatory Mechanisms of Pro- and Anti-Cancer Activity and Their Impact on Immunotherapy. Cancers 2023; 15(6): 1642 doi: 10.3390/cancers15061642
|
| 19 |
Ming Yan, Li-yuan Xiao, Martin Gosau, Ralf Smeets, Hong-chao Feng, Simon Burg, Ling-ling Fu, Reinhard E. Friedrich. The role of herpes simplex virus infection in the etiology of head and neck cancer–a Mendelian randomization study. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1278327
|
| 20 |
Ze Zhang, Kartik Sehgal, Keisuke Shirai, Rondi A. Butler, John K. Wiencke, Devin C. Koestler, Geat Ramush, Min Kyung Lee, Annette M. Molinaro, Hannah G. Stolrow, Ariel Birnbaum, Lucas A. Salas, Robert I. Haddad, Karl T. Kelsey, Brock C. Christensen. Methylation cytometric pretreatment blood immune profiles with tumor mutation burden as prognostic indicators for survival outcomes in head and neck cancer patients on anti-PD-1 therapy. npj Precision Oncology 2024; 8(1) doi: 10.1038/s41698-024-00759-8
|